Gulbarga Institute of Medical Sciences in Kalaburagi is facing an acute shortage of anti-rabies vaccine due to a shortage in drug supply, an official said on Saturday.
Girish, who brought his daughter for vaccination, was left disappointed after the hospital authorities informed him that no injection was available.
"I brought my daughter to this hospital for injection as she was bitten by a dog. Now, the hospital authorities told me that there is a shortage of injections. For people like us, treatment in a private hospital is expensive. Who will be responsible if something happens to her?" he asked.
When asked about the issue, Medical Superintendent GIMS hospital, Shivakumar accepted that there has been a shortage of vaccines and told ANI that the institute is dependent on Karnataka government for the supply of vaccines.
"There is a shortage of anti-rabies vaccines. There are issues from manufacturing units somewhere around in Tamil Nadu. We are facing this problem for over one month. We have brought it to the notice of our Director and he has discussed the issue with Director of Medical Education in Bangalore which comes under Karnataka government," he said.
Shivakumar continued, "They have asked us to take it from local distributors available in the market. Last time, we managed to buy it from local distributors but now we are facing issues again. We have now contacted the local distributors to buy vaccines. The shortage in our hospital is also due to its high demand."
Rabies is a zoonotic infection (a disease that spreads from animals to humans) that can cause a rare but life-threatening infection of the brain and nervous system in humans. It usually results from a bite, scratch or lick from an infected animal.
The virus is estimated to kill around 59,000 people every year worldwide, most often as a result of a bite from a rabid dog in parts of Africa and Asia.
Rabies does not circulate in wild or domestic animals; although some species of bats can carry rabies-like viruses (European Bat Lyssavirus type 1 and type 2).
As per reports, in India, the vaccine costs around Rs 300 in the market. However, it is provided free of cost in government hospitals.
Providing treatment to the infected person within 10 days of infection is considered an effective way of preventing the ailment from becoming worse.
.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
